MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion

Wang, Hui-Ju; Ruan, Hong-Jun; He, Xu; Ma, Yingyu; Jiang, Xiaoting; Xia, Yingjie; Ye, Zai-yuan; Tao, Hou‐Quan

doi:10.1016/j.ejca.2010.05.012

Cited by 225 publications

(160 citation statements)

References 22 publications

Supporting

Mentioning

148

Contrasting

Order By: Relevance

“…Of all the different expression microRNA, the significant downregulation of miR-101 in cervical cancers of Uygur women is consistent with the reported decrease of miR-101 in prostate cancer (Pang et al, 2010;), colon (Chandramouli et al, 2012Strillacci et al, 2013), liver cancer (Zhang et al, 2012), non small cell lung cancer (Zhang et al, 2011), breast cancer (Wang et al, 2012), and gastric cancer (Wang et al, 2010). Our data showed that miR-101 expression was significantly reduced in cervical cancer, which may play a critical role in the occurrence and development of cervical cancer.…”

Section: Discussionsupporting

confidence: 69%

Roles of MiR-101 and its Target Gene Cox-2 in Early Diagnosis of Cervical Cancer in Uygur Women

Chen¹,

Huang²,

Zhang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 69%

Roles of MiR-101 and its Target Gene Cox-2 in Early Diagnosis of Cervical Cancer in Uygur Women

Chen¹,

Huang²,

Zhang³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Previous studies have screened for and identified a subset of miRNAs that are associated with gastric cancer, indicating their extensive participation in the development and progression of gastric cancer (7,8). However, the biological function and mechanisms of many of these miRNAs remains unknown.…”

Section: Identification and Characterization Of Tumor Suppressor And mentioning

confidence: 99%

Identification and characterization of tumor suppressor and oncogenic miRNAs in gastric cancer

Chen

Liu

et al. 2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The aim of the present study was to screen for and identify microRNAs (miRNAs/miRs) that are associated with gastric cancer and to clarify the role of these miRNAs in gastric cancer. Thus, the differential expression of a panel of miRNAs in two pairs of gastric cancer tissues and their matched adjacent healthy tissues was investigated by performing a microarray analysis. To verify the results of this screen, 56 gastric cancer tissues were analyzed for the selected miRNAs using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The association between the expression of a specific miRNA and the clinical data relating to the tissue samples [including age, gender, tumor size, tumor node metastasis (TNM) stage and lymph-node metastasis] were subsequently examined. A total of 31 differentially expressed miRNAs were identified in the miRNA array. Using RT-qPCR to verify these results, it was determined that 10 miRNAs exhibited high mRNA expression levels and 13 miRNAs exhibited a low expression in the gastric cancer tissue samples, while 8 miRNAs did not demonstrate an association with gastric cancer. Thus, the microarray and RT-qPCR results demonstrated 74.2% (23/31 miRNAs) agreement. The association between the 23 miRNAs and the clinicopathological characteristics of the gastric cancer samples was investigated. It was identified that the expression levels of miR-551b-3p, miR-133b, miR-100-5p and miR-363-3p were significantly downregulated in the gastric cancer tissues, and this downregulation was closely correlated with the degree of differentiation (i.e., tumor grade), TNM stage and lymph-node metastasis (P<0.05). By contrast, the expression of miR-215 was significantly upregulated in the gastric cancer tissues, and its expression level was correlated with tumor differentiation, TNM stage and lymph-node metastasis (P<0.05). Furthermore, miR-200a-3p was upregulated in the gastric cancer tissues and its expression was significantly more prevalent in male patients compared with female patients (P<0.05). miR-429 was upregulated in the gastric cancer tissues and its expression was significantly higher in patients who were >50 years of age (P<0.05). These data indicate that a number of these miRNAs may be important in the development of gastric cancer. In particular, miR-551b-3p, miR-133b, miR-100-5p and miR-363-3p may act as tumor suppressors in the development of gastric cancer. By contrast, miR-215 appears to exhibit oncogenic properties and promote the development of gastric cancer. In addition, the abnormal expression of miR-200a-3p may be associated with gender, while the abnormal expression of miR-429 may be associated with age in patients with gastric cancer. However, additional studies are required to delineate the underlying mechanisms of the association, and to explore their potential as valid biomarkers in the diagnosis, classification and prognosis of gastric cancer.

show abstract

“…[2][3][4] Previous studies have shown that many miRNAs are aberrantly overexpressed or downregulated during gastric cancer progression, including miR- 16, miR-21, miR-101, miR-126, miR-129, miR-181c, miR-196b and -200. [5][6][7][8][9][10][11][12] These miRNAs could play oncogenic or tumor-suppressive functions in the regulation of cell growth, apoptosis and cell migration by repressing their target genes.…”

Section: Introductionmentioning

confidence: 99%

Aberrant hypermethylation ofmiR-9genes in gastric cancer

Tsai

Liao²,

Wu³

et al. 2011

Epigenetics

105

View full text Add to dashboard Cite

MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion

Cited by 225 publications

References 22 publications

Roles of MiR-101 and its Target Gene Cox-2 in Early Diagnosis of Cervical Cancer in Uygur Women

Roles of MiR-101 and its Target Gene Cox-2 in Early Diagnosis of Cervical Cancer in Uygur Women

Identification and characterization of tumor suppressor and oncogenic miRNAs in gastric cancer

Aberrant hypermethylation ofmiR-9genes in gastric cancer

Contact Info

Product

Resources

About